The largest database of trusted experimental protocols

4 protocols using cd8 pe cy7 clone sk1

1

T Cell Activation Analysis in PBMC Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMC samples were stained with the following antibodies for T cell activation analysis: CD3-BV510 (clone OKT3), CD4-BV421 (clone OKT4), CD8-PE-Cy7 (clone SK1), HLA-DR-FITC (clone L243; Biolegend, San Diego, CA, USA); CD38-APC (clone HIT2; BD Biosciences, San Diego, CA, USA). The BD Canto II instrument (BD Biosciences, San Diego, CA, USA) was used for data collection, and the data was analyzed using FlowJo software V10 (Tree star Inc., Ashland, OR, USA).
+ Open protocol
+ Expand
2

Comprehensive Immune Profiling of PBMC Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood mononuclear cells (PBMC) were isolated from fresh venous blood using Ficoll density gradient. PBMC samples were stained with the following antibodies: CD3-APC-Cy7 (clone HIT3a), CD3-BV510 (clone OKT3), CD4-BV421 (clone OKT4), CD8-PE-Cy7 (clone SK1), CD45RA-BV510 (clone HI100), CCR7-APC (clone G043H7), CD27-FITC (clone MT271), HLA-DR-FITC (clone L243), CXCR5-BV421 (clone J252D4), PD-1-PE (clone EH12.2H7), CXCR3-BV510 (clone G025H7), CCR4-PerCP-Cy5.5 (clone L291H4), CCR6-PE (clone G034E3), CD25-APC (clone BC96), CD127-FITC (clone A019D5), Perforin-PE-Cy7 (dG9), Granzyme B-AF647 (GB11) were purchased from Biolegend (San Diego, CA); CD4-percp (clone SK3), CD38-APC (clone HIT2), Tim-3-PE (clone 7D3), GNLY-AF488 (clone RB1) were obtained from BD Biosciences (San Diego, CA). Granzyme B, Perforin and GNLY were measured de novo, without prior stimulation with PMA/ionomycin. BD Canto II instrument was used for FACS and the data was analyzed using FlowJo software V10 (Tree star Inc. Ashland, OR).
+ Open protocol
+ Expand
3

SARS-CoV-2 Spike Protein T-cell Response

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMC from healthy donors (n=6) (collected before 2020) and patients with COVID-19 who recovered (n=22) were thawed and resuspended at 1×107 cells/ml in RPMI supplemented with 5% human serum. 100μL of cell suspension (1×106 cells) was transferred to wells of a 96-well U-bottom plate containing purified SARS-CoV-2 spike protein (40μg/mL) or media alone. After 24 h in a 37°C/5% CO2 incubator, Golgistop (BD Biosciences, Cat#554724) was added for 6 h. The cells were harvested, fixed and permeabilized (BD, Phosflow FIX I (Cat#557870, Phosflow Perm III Cat#558050) and stained with antibodies to CD3 (BV650) (clone OKT3, Cat#317323, CD4 (APC/Fire750) (clone A161A1, Cat#357425, CD8 (PE/Cy7)(clone SK1, Cat#344711), CD25 APC-CD25 (Clone MA-251, Cat#356110), IL-17A (PE Dazzle 594, BL168, Cat512335), and IFNγ (FITC)(clone 4S.B3, Cat#502505) according to the manufacturer’s instructions (Biolegend, San Diego, CA). The cells were analyzed on a FACS analyzer (BD LSRFortessa). Electronic gates were placed on live CD4+ or CD8+ cells using FlowJo software (BD Biosciences, Ashland, OR) and the proportions of CD25+ or IFN-γ+ cells were measured. The percentage positive was determined by comparison to an isotype control antibody.
+ Open protocol
+ Expand
4

Multiparameter Flow Cytometry of T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following anti-human antibodies were used for the flow cytometry assays: CD3 A700 (clone SK7; BioLegend, San Diego, CA), CD8 PE-Cy7 (clone SK1; BioLegend) PD-1 FITC (clone EH12.2H7; BioLegend), LAG-3 PerCPCy5.5 (clone 11C3C65; BioLegend), For the surface stain, mAbs against cell markers were added to a total of 1 × 106 cells in 1X PBS containing 1% FBS and 0.1% sodium azide (FACS buffer) for 45 min at 4°C. After washing twice with FACS buffer, cells were fixed in PBS containing 2% paraformaldehyde (Sigma-Aldrich, St. Louis, MO). For each sample, 100,000 total events were acquired on the BD LSRII. Ab capture beads (BD Biosciences) were used as individual compensation tubes for each fluorophore in the experiment. To define positive and negative populations, we used fluorescence minus controls for each fluorophore. Furthermore, we optimized gating by examining known negative cell populations for background expression levels similar to that used in our previous work (7 (link)). Briefly, we gated single cells, dump cells, viable cells (Aqua Blue), lymphocytes, CD3+ cells, and CD8+ cells before finally gating human epitope-specific CD8+ T cells using HSV-specific tetramers (Figure S1). Data analysis was performed using FlowJo software (BD Biosciences, San Jose, CA). Statistical analyses were done using GraphPad Prism version 5 (La Jolla, CA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!